EMA Authorised: Inflectra (infliximab) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA authorised Inflectra (infliximab) as a biosimilar to Remicade for multiple inflammatory diseases including rheumatoid and psoriatic arthritis, ankylosing sp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• INFLECTRA (infliximab-dyyb)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Spondylitis, Ankylosing;Colitis, Ulcerative;Psoriasis;Crohn Disease;Arthritis, Rheumatoid. MAH: Pfizer Europe MA EEIG. Decision date: 16/02/2026